Skip to main content
H

Hutchmed (China) Limited — Investor Relations & Filings

Ticker · HCM ISIN · KYG4672N1198 LEI · 2138006X34YDQ6OBYE79 HKEX Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country KY Cayman Islands
Listing HKEX HCM

About Hutchmed (China) Limited

https://www.hutch-med.com/

Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.

Recent filings

Filing Released Lang Actions
Blocklisting Six Monthly Return
Regulatory Filings Classification · 1% confidence The document is a 'Blocklisting Six Monthly Return' filed via the London Stock Exchange's RNS (Regulatory News Service). It details the issuance of shares under a specific share option scheme over a six-month period. While it involves share issuance, it is a standard regulatory disclosure of blocklisting activity rather than a discretionary capital raise or a share buyback (POS). Given that it is a routine regulatory filing regarding share schemes, 'RNS' is the most appropriate classification as it serves as a general regulatory announcement.
2025-12-29 English
6-K
Foreign Filer Report
2025-12-17 English
HUTCHMED Initiates Development of ATTC Candidate
Regulatory Filings Classification · 1% confidence The document is a press release issued by HUTCHMED (China) Limited regarding the initiation of a global Phase I clinical trial for a new drug candidate (HMPL-A251). It is distributed via the RNS (Regulatory News Service) 'Reach' platform, which is used for non-regulatory corporate announcements. Since it is a press release announcing clinical trial progress rather than a formal financial report, a proxy statement, or a mandatory regulatory filing, it falls under the general category of regulatory announcements/press releases.
2025-12-17 English
6-K
Foreign Filer Report
2025-12-08 English
Expanded NRDL Coverage + CIDL Inclusion in China
Regulatory Filings Classification · 1% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding the inclusion of specific drugs in China's National Reimbursement Drug List (NRDL). It is a corporate announcement detailing operational and regulatory updates rather than a financial report, audit, or proxy statement. As it does not fit into more specific categories like M&A or dividend announcements, it falls under the general regulatory filing category.
2025-12-08 English
6-K
Foreign Filer Report
2025-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.